U.S. Continuous Renal Replacement Therapy Market Estimated To Experience A Hike In Growth By 2028

U.S. Continuous Renal Replacement Therapy Industry Overview

The U.S. continuous renal replacement therapy market size is expected to reach USD 957.2 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.1% from 2021 to 2028. The U.S. market is expected to grow owing to the growing number of ICU patients with Acute Kidney Injury (AKI), along with the increasing incidence of sepsis. Moreover, COVID-19 has positively impacted the market growth. In addition, the presence of well-established key players in the country focusing on developing and commercializing technologically advanced devices and initiatives undertaken by the government to increase the awareness about continuous renal replacement therapy (CRRT) is expected to boost the market growth during the forecast period.

 

U.S. Continuous Renal Replacement Therapy Market Segmentation

Grand View Research has segmented the U.S. continuous renal replacement therapy market on the basis of product and modality:

 

Based on the Product Insights, the market is segmented into CRRT System, Disposables, and Liquids

• In 2020, the liquids segment dominated the U.S. market with a revenue share of over 60.0%. The liquid segment comprises dialysates, renal replacement fluids, anticoagulants, and saline. Increasing demand for CRRT in the treatment of hemodynamically unstable patients and the growing number of manufacturers supplying dialysate and replacement fluids for RRT are among factors contributing to the segment growth.
• The disposables segment is projected to expand significantly during the forecast period owing to the increasing use of hemofilter, fluids, charcoal filters, and other consumables in CRRT treatments. The disposables segment mainly includes disposable treatment kits/infusion kits, hemofilter, and bloodlines. These products are low-priced, used frequently, and of high quality.
• Furthermore, consumables used during CRRT must be replaced after each setup to minimize contamination. Contaminated consumables such as recycled fistula needles can endanger a patient’s life. As a result of a large replacement rate of consumables owing to low pricing, their demand is likely to increase, thereby promoting segment growth. Moreover, factors such as the increasing prevalence of AKI and the growing emphasis on effective CRRT among ICU patients are boosting the demand for disposables.

 

Based on the Modality Insights, the market is segmented into Slow Continuous Ultrafiltration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF)

• In 2020, the continuous venovenous hemodialysis (CVVHD) segment dominated the market with a volume share of over 30.0% in terms of procedure/treatment. The CVVHD treatment modality has high efficacy with low blood flows.
• Moreover, the U.S. CRRT market for CVVHD is expected to grow due to the use of smaller, less invasive catheters and longer filter running times compared to convective treatment modalities. For instance, Ci-Ca CVVHD with Ultraflux EMiC 2 filter developed and manufactured by Fresenius Medical Care is an advanced CRRT therapy, combining the advantages of CVVHD with better removal of middle molecules while retaining essential plasma proteins such as albumin and cellular blood constituents. Such developments are expected to support the segment growth over the forecast period.
• The continuous venovenous hemodiafiltration (CVVHDF) segment is expected to expand at the highest volume-based CAGR of 6.25% from 2021 to 2028. The increasing prevalence of fluid overload cases, which is frequently found in AKI patients in critical care units, is expected to propel the growth of the CVVHDF segment over the forecast period. Moreover, according to an article published by the American Society of Nephrology, congestive heart failure, which accounts for approximately 8% of all-cause mortality in patients at stages 4 & 5 of CKD, is associated closely with fluid overload, which is likely to increase the application of CVVHDF treatment procedure. These factors are further expected to fuel the segment growth over the forecast period.

 

Key Companies Profile & Market Share Insights

Key players are adopting various strategies to gain a greater market share such as new product launches and mergers and acquisitions. In May 2021, Baxter unveiled its PrisMax 2 System to advance critical care delivery for patients. It is the latest version of the company’s next-generation platform intended to streamline the delivery of CRRT and other organ support therapies.

Some prominent players in the U.S. continuous renal replacement therapy market include:

• Baxter
• Braun Melsungen AG
• Fresenius Medical Care AG
• Medtronic
• Asahi Kasei Medical Co., Ltd.
• Nipro Corporation

 

Order a free sample PDF of the U.S. Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.